NASDAQ · Biotechnology · USD
PharmaCyte Biotech, Inc. (PMCB) Stock Analysis
PharmaCyte Biotech, Inc. (PMCB) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
PMCB Key Statistics
As of Oct 21, 2026Trading
- Open
- $0.34
- Previous Close
- $0.34
- Day's Range
- 0.34–0.37
- 52-Week Range
- 0.33–1.51
- Volume
- 50.85K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.68
Valuation
- Market Cap
- $3.73M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −2.31
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- $30.66M+9,084.98%
- Shares Outstanding
- 10.74M
- 1-Year Return
- −64.50%
Dividend and dates
- Avg Volume
- 200.87K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, PMCB closed at $0.35, −64.50% over 1 year.
PharmaCyte Biotech, Inc. (PMCB) has a market capitalization of $3.73M.
In fiscal 2024, PMCB reported revenue of $0.00.
PMCB Stock Return by Calendar Year
PharmaCyte Biotech, Inc. (PMCB) 10-year return: what $10,000 became
- 1 year
- $10,000 $3,550
- −64.50%
- 5 years
- $10,000 $1,198
- −88.02%
- 10 years
- $10,000 $58
- −99.42%
If you had invested $10,000 in PharmaCyte Biotech, Inc. (PMCB) 10 years ago, at the close on October 21, 2016, it would have been worth $58 at the close on October 21, 2026: −99.42% in total, −40.28% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −52.03% |
| 2025 | −53.89% |
| 2024 | −27.31% |
| 2023 | −26.28% |
| 2022 | +17.20% |
| 2021 | −75.93% |
| 2020 | −83.46% |
| 2019 | +9.46% |
| 2018 | −33.69% |
| 2017 | −62.53% |
| 2016 (partial year) | +242.30% |
As of October 21, 2026.
PMCB Revenue and Earnings by Fiscal Year
FY ends April| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2024 | $0.00 | $30.66M | — |
| 2023 | $0.00 | $333.76K | — |
| 2022 | $0.00 | −$4.32M | — |
| 2021 | $0.00 | −$4.24M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2024 | $0.00 | — | −$4.38M | $30.66M | — |
| 2023 | $0.00 | — | −$6.52M | $333.76K | — |
| 2022 | $0.00 | — | −$6.46M | −$4.32M | — |
| 2021 | $0.00 | — | −$4.39M | −$4.24M | — |
Annual figures as reported, in the company's reporting currency. As of April 30, 2025.
Recent News
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B